Zalicus Inc. (ZLCS) Reports Financial Results For The First Quarter 2014
5/9/2014 7:47:18 AM
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the first quarter ended March 31, 2014.
“This was a significant quarter for Zalicus as we announced our intended merger with Epirus Biopharmaceuticals with the goal of creating a Nasdaq-listed company focused on building a global biosimilar enterprise to improve patient access to essential medicines,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus.
Help employers find you! Check out all the jobs and post your resume.
comments powered by